Navigation Links
GeneThera Extends its Reach Overseas
Date:6/16/2009

Results from Pharma Finance 2009

ARVADA, Colo., June 16 /PRNewswire-FirstCall/ -- GeneThera, Inc. (OTC: GTHR.PK). GeneThera, as a service and responsibility to our shareholders, is addressing our recent events.

GeneThera Inc. recently attended Pharma Finance 2009, a Biotechnology, Medical Devices, and world public and private Finance Conference in Rome, Italy on June 4-5.

Pharma Finance is an international event addressing new technologies for Life Sciences, concentrating on Biotechnology, finance, nano-technology and innovative materials.

The Lazio Region and Sviluppo Lazio S.p.A. jointly organized Pharma Finance, in collaboration with the Ministry for International Commerce, ICE, Filas S.p.A. and the Zangani Investor Community.

During the two-day event big pharma, small and medium size enterprises, research and university centers presented their products, research projects and technologies. The Conference foreign delegation session fostered the internationalization process taken by many businesses, to develop international cooperation; the presence of Business Angels and Venture Capitalist provided useful information to new entrepreneurial activities.

Dr. Milici comments, "We felt that this particular conference provided us the opportunity to meet with companies outside the United States, such as Canada and Italy, but also emerging nations such as The United Arab Emirates and Singapore to name a few. We feel that the safety of the world's food system can be protected by our proprietary technology, which stems from our vast expertise in creating solutions from microbiology and genetics."

As a result of the attendance at Pharma Finance 2009, GeneThera is in talks with the University of Rome, who is also working on a vaccine for Johne's disease and looking to collaborate on the activities in Mexico. In addition, GeneThera will be looking to expand its investor base by applying for the TSX Venture Exchange after speaking with the exchange's vice president.

As discussions progress, the company will release more details.

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Arvada, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For more information, contact Dr. Tony Milici at 303-463-6371 or Richard Dopkin at JR Dopkin & Associates LLC at 516-884-3200.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.


'/>"/>
SOURCE GeneThera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine
2. [video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.nets 3-Minute Press Show
3. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
4. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
5. BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009
6. BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009
7. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
8. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
9. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
10. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
11. Ziehm Imaging Extends its Training Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017   Sienna Biopharmaceuticals, Inc. , a ... announced that Richard Peterson will join the ... Peterson, who brings more than two decades of ... who is retiring at the end of April but ... Peterson joins Sienna from Novan, Inc., where he served ...
(Date:3/23/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Global Market for Bioproducts Should ... at a CAGR of 8.9%, This research ... into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
Breaking Biology News(10 mins):